Ziv-aflibercept |
| カタログ番号GC70299 |
Ziv-afliberceptは血管内皮成長因子（VEGF）の可溶性抑制剤である。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1609655-49-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Ziv-aflibercept (0.25, 0.5, 1.0 and 5 mg/mL; 24 h) reduces mitochondrial membrane potential in ARPE-19 cells with dose dependent manner[1].
Ziv-aflibercept (25 mg/mL; intravitreal injection; single dose) insignificantly causes cataract, retinal detachment and other related complications in the right eye of the rabbit[2].
References:
[1]. Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16.
[2]. de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *